The Technical Analyst
PAVmed Inc. [PAVMW]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Medical - Devices
PAVmed Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
105.67% $0.0290
/ 28 jan 2022 @ 12:36
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.770 mill |
| EPS: | -0.576 |
| P/E: | -0.0500 |
| Earnings Date: | Jun 30, 2022 |
| SharesOutstanding: | 26.54 mill |
| Avg Daily Volume: | 0.0066 mill |
| RATING 2022-02-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0500 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0500 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0660 - 0.124 ( +/- 327.59%) |
| ATR Model: 14 days |
Forecast:
01:40 - $-0.406
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0290 (105.67% ) |
| Volume | 0.0326 mill |
| Avg. Vol. | 0.0066 mill |
| % of Avg. Vol | 497.12 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PAVMW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PAVMW
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.
Last 10 Buy Signals
| Date | Signal | @ |
|---|---|---|
| VEI.OL | Apr 19 - 06:56 | NOK113.00 |
| DNB.OL | Apr 19 - 06:52 | NOK210.80 |
| ELK.OL | Apr 19 - 06:52 | NOK19.39 |
| RECSI.OL | Apr 19 - 06:51 | NOK10.74 |
| PEPECOINUSD | Apr 19 - 07:05 | 5.12 |
| SPOL.OL | Apr 19 - 06:50 | NOK127.22 |
| AUSS.OL | Apr 19 - 06:44 | NOK82.90 |
| DEXEUSD | Apr 19 - 07:03 | 12.82 |
| NRC.OL | Apr 19 - 06:50 | NOK11.85 |
| KID.OL | Apr 19 - 06:41 | NOK147.00 |
Latest News
2020-08-18 20:14:00 - Yahoo
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
Conference call to be held today at 4:30 p.m. Eastern timeNEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today reported financial results for the three and six months ended June 30, 2020 and provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”) and Solys Diagnostics Inc. (“Solys”).“The second quarter of 2020 and subsequent weeks constitute an unprecedented period of major accomplishments for PAVmed and its subsidiaries, despite significant Covid-19 headwinds in the late spring and early summer,” said Lishan Aklog, M...
2020-08-06 13:27:00 - Yahoo
PAVmed Secures $7 Million Convertible Note Financing
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has received approximately $7 million in gross proceeds from a private placement (the “Financing”) of Senior Convertible Promissory Notes with an existing institutional investor. Proceeds from the Financing will support the Company’s commercialization, regulatory and product development activities, including the commercialization of EsoGuard™/EsoCheck™ and CarpX™, its EsoGuard BE-1 and BE-2 clinical trials and for general working capital purposes.The Financing is led by an existing institutional investor who participated in senior convertible promissory note financings with similar terms in December 2018, November 2019, and April 2020...
2020-08-05 13:00:00 - Yahoo
LD Micro Announces Preliminary List of Presenters for the LD-500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
2020-07-28 13:30:00 - Yahoo
PAVmed to Hold Business Update Conference Call on August 18, 2020
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Tuesday, August 18, 2020 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s President and Chief Financial Officer, will discuss second quarter 2020 financial results. To access the conference call, U...
2020-07-13 13:30:10 - Yahoo
PAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020
NEW YORK, July 13, 2020 -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today.
2020-05-27 21:08:50 - Yahoo
Should You Buy PAVmed Inc. (PAVM)?
In this article we will take a look at whether hedge funds think PAVmed Inc. (NASDAQ:PAVM) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from […]
2020-04-28 06:16:42 - THELINCOLNIANONLINE
PAVmed Inc (NASDAQ:PAVM) Sees Large Increase in Short Interest
PAVmed Inc (NASDAQ:PAVM) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,760,000 shares, a growth of 36.4% from the March 31st total of 1,290,000 shares. Currently, 5.8% of the shares of the company are short sold. Based on an […]
2020-04-22 14:12:02 - Yahoo
Company News for Apr 22, 2020
2020-04-10 07:19:38 - YAHOO
Edited Transcript of PAVM earnings conference call or presentation 9-Apr-20 8:30pm GMT
2020-04-05 18:03:32 - YAHOO
The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts and pre-announcements in light of the COVID-19 impact.The stock that made headlines during the week was Amarin Corporation plc